title: Bacterial meningitis from Rothia mucilaginosa in patients with malignancy or undergoing hematopoietic stem cell transplantation.
abstract: Opportunistic infections contribute to morbidity and mortality of patients undergoing hematopoietic stem cell transplantation and treatment for malignancies. Rothia mucilaginosa, a gram-positive bacterium, is responsible for rare, but often fatal meningitis in severely immunocompromised patients. We describe two cases of meningitis from discrete strains of R. mucilaginosa on our pediatric bone marrow transplant unit, summarize the published cases of R. mucilaginosa meningitis in oncology and stem cell transplant patients, and provide updated recommendations regarding the use of antibiotic therapy in this patient population.
authors.affiliation: University of Minnesota Medical School, Minneapolis, Minnesota, USA.
authors.forename: Alisa B
authors.initials: AB
authors.lastname: Lee
authors.forename: Paul
authors.initials: P
authors.lastname: Harker-Murray
authors.forename: Patricia
authors.initials: P
authors.lastname: Ferrieri
authors.forename: Mark R
authors.initials: MR
authors.lastname: Schleiss
authors.forename: Jakub
authors.initials: J
authors.lastname: Tolar
mesh_terms: D000193:Actinomycetales Infections / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology*; D000293:Adolescent; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002442:Ceftazidime / Q000008:administration & dosage / Q000627:therapeutic use; D002557:Cerebrospinal Fluid Shunts; D002648:Child; D036101:Cord Blood Stem Cell Transplantation; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D016867:Immunocompromised Host; D007947:Leukemia, Megakaryoblastic, Acute / Q000601:surgery*; D008297:Male; D016920:Meningitis, Bacterial / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology* / Q000601:surgery; D000077731:Meropenem; D008835:Micrococcaceae / Q000302:isolation & purification*; D009894:Opportunistic Infections / Q000188:drug therapy / Q000209:etiology / Q000382:microbiology*; D011183:Postoperative Complications / Q000209:etiology / Q000382:microbiology*; D012293:Rifampin / Q000008:administration & dosage / Q000627:therapeutic use; D018805:Sepsis / Q000209:etiology; D013845:Thienamycins / Q000008:administration & dosage / Q000627:therapeutic use; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D000900:Anti-Bacterial Agents; D013845:Thienamycins; D014640:Vancomycin; D002442:Ceftazidime; D000077731:Meropenem; D012293:Rifampin